Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea

Pediatric Blood and Cancer

Volumn 56, Issue 1, 2011, Pages 90-94

  Tripathi, Avnish ^a   Jerrell, Jeanette M ^b   Stallworth, James R ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Hydroxyurea; Pediatrics; Sickle cell disease

Indexed keywords

HYDROXYUREA; PENICILLIN G;

ACUTE CHEST SYNDROME; ADOLESCENT; ARTICLE; BONE NECROSIS; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CHOLECYSTITIS; CONTROLLED STUDY; DRUG ERUPTION; ETHNICITY; FEMALE; GALLSTONE; GENDER; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; HYPERSPLENISM; KIDNEY FAILURE; LEG ULCER; LEUKEMIA; LIVER DISEASE; LUNG COMPLICATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAID; NEUTROPENIA; PNEUMONIA; POLYURIA; PRIAPISM; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; RETINOPATHY; SEIZURE; SICKLE CELL ANEMIA; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; STROKE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; WEIGHT GAIN;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; FEMALE; HOMOZYGOTE; HUMANS; HYDROXYUREA; INFANT; INFANT, NEWBORN; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; MALE; MEDICAID; UNITED STATES;

EID: 78649657057     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22822     Document Type: Article

References (33)

1. CDC. 2009 May 12. Facts about Sickle Cell Disease: Data & Statistics. Centers for Disease Control and Prevention. Accessed 2010 May 12.
2. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932-938.
3. DeBaun MR, Vichinsky E. Hemoglobinopathies. In: Kliegman RM, Behrman RE, Jenson HB, Stanton B, editors. Nelson textbook of pediatrics, 18th edition. Philadelphia: WB Saunders Elsevier; 2007.
4. Bender MA, Hobbs W. Sickle cell disease. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene Reviews [Internet], University of Washington: Seattle, WA; 1993; 2003 Sep 15 [updated 2009 Sep 17].
5. Steinberg MH. Sickle cell anemia, the first molecular disease: Overview of molecular etiology, pathophysiology, and therapeutic approaches. Sci World J 2008; 8: 1295-1324.
6. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005; 129: 465-481.
7. Bachmeyer C, Aractingi S, Lionnet F. Hydroxyurea for sickle cell anemia. N Engl J Med 2008; 359: 98, author reply 98-99.
8. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 1997; 34: 15-21.
9. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79: 2555-2565.
10. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652-656.
11. de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes. Haematologica 2006; 91: 125-128.
12. Anderson N. Hydroxyurea therapy: Improving the lives of patients with sickle cell disease. Pediatr Nurs 2006; 32: 541-543.
13. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996; 88: 1960-1964.
14. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148: 939-955.
15. Wiles NM, Howard J. Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease. Ther Risk Manage 2009; 5: 745-755.
16. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94: 1550-1554.
17. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008; 122: 1332-1342.
18. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97: 3628-3632.
19. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103: 2039-2045.
20. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology/The Education Program of the American Society of Hematology American Society of Hematology Education Program 2009; 62-69.
21. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005; 106: 2269-2275.
22. Hoppe C, Vichinsky E, Quirolo K, et al. Use of hydroxyurea in children ages 2-5 years with sickle cell disease. J Pediatr Hematol Oncol 2000; 22: 330-334.
23. Thompson BW, Miller ST, Rogers ZR, et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatr Blood Cancer 54: 250-255.
24. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep) 2008; 1-95.
25. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
26. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001; 139: 790-796.
27. Stallworth JR, Jerrell JM, Tripathi A. Cost-effectiveness of hydroxyurea in reducing the incidence of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol 2010; May 24 [Epub ahead of print].
28. Raphael JL, Dietrich CL, Whitmire D, et al. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer 2009; 52: 263-267.
29. Valafar H, Valafar F, Darvill A, et al. Predicting the effectiveness of hydroxyurea in individual sickle cell anemia patients. Artif Intell Med 2000; 18: 133-148.
30. Mankad VN. Exciting new treatment approaches for pathyphysiologic mechanisms of sickle cell disease. Pediatr Pathol Mol Med 2001; 20: 1-13.
31. Heeney MM, Howard TA, Zimmerman SA, et al. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med 2003; 141: 279-282.
32. Hoppe C, Klitz W, Cheng S, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 2004; 103: 2391-2396.
33. Grosse SD, Boulet SL, Amendah DD, et al. Administrative data sets and health services research on hemoglobinopathies: A review of the literature. Am J Prev Med 2010; 38: S557-S567.